William Blair analyst Sami Corwin has maintained their bullish stance on TNYA stock, giving a Buy rating on March 6.
Sami Corwin has given his Buy rating due to a combination of factors related to Tenaya Therapeutics’ promising clinical developments. The company is actively advancing its MyPEAK-1 trial for TN-201, targeting MYBPC3-associated hypertrophic cardiomyopathy, with updated clinical data set to be presented at a significant medical conference. This includes safety data and biopsy results from the initial patient cohort, indicating progress in their clinical trials.
Additionally, Tenaya is making strides with its RIDGE-1 Phase Ib trial for TN-401, aimed at treating PKP2-associated arrhythmogenic right ventricular cardiomyopathy. The company’s strategic timeline for enrollment and data sharing, coupled with its efforts in pediatric studies and natural history research, underscores its commitment to addressing unmet medical needs. These developments suggest potential for future growth and innovation, supporting the Buy rating by Sami Corwin.
In another report released on March 6, Leerink Partners also maintained a Buy rating on the stock with a $3.00 price target.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TNYA in relation to earlier this year.